Pharmaceuticals
Changing Prescription Patterns in Pharmacologically Treated Patients with Newly Diagnosed Inflammatory Bowel Disease in German Gastroenterology Practices: A Real-World Study, 2015-2024
By Fernandez Milano A, Krieg S and Kostev K.
Abstract
Background/Objectives: The therapeutic landscape of inflammatory bowel disease (IBD) has evolved, particularly with the expanding availability of biologic and targeted therapies. This study characterized real-world prescribing patterns among patients with newly diagnosed Crohn's disease (CD) and ulcerative colitis (UC) in Germany.
Methods
This retrospective study used the German IQVIA Disease Analyzer database. Patients aged 15-80 years diagnosed with CD or UC between 2015 and 2024, with ≥12 months of follow-up and at least one predefined treatment prescription within 12 months after diagnosis, were included. Prescription patterns were compared by IBD subtype, diagnosis period (2015-2019 vs. 2020-2024), age, and sex. Associations were assessed using multivariable logistic regression.